EphA2 expression is associated with aggressive features in ovarian carcinoma

被引:180
作者
Thaker, PH
Deavers, M
Celestino, J
Thornton, A
Fletcher, MS
Landen, CN
Kinch, MS
Kiener, PA
Sood, AK
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA
[3] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA
[4] Medimmune Inc, Gaithersburg, MD 20878 USA
关键词
D O I
10.1158/1078-0432.CCR-03-0589
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: EphA2 (epithelial cell kinase) is a transmembrane receptor tyrosine kinase that has been implicated in oncogenesis. There are no published data regarding the role of EphA2 in ovarian carcinoma, which is the focus of the present study. Experimental Design: Nontransformed (HIO-180) and ovarian cancer (EG, 222, SKOV3, and A2780-PAR) cell lines were evaluated for EphA2 by Western blot analysis. Five benign ovarian masses, 10 ovarian tumors of low malignant potential, and 79 invasive ovarian carcinomas were also evaluated for EphA2 expression by immunohistochemistry. All samples were scored in a blinded fashion. Univariate and multivariate analyses were used to determine significant associations between EphA2 expression and clinicopathological variables. Results: By Western blot analysis, EG, 222, and SKOV3 cell lines overexpressed EphA2, whereas A2780-PAR and HIO-180 had low to absent EphA2 expression. All of the benign tumors had low or absent EphA2 expression. Among the invasive ovarian carcinomas examined (mean age of patients was 59.2 Years), 60 (75.9%) tumors overexpressed EphA2 and the other 19 tumors had negative or minimal EphA2 expression. There was no association of EphA2 overexpression with ascites, likelihood of nodal positivity, pathological subtype, and optimum surgical cytoreduction (residual tumor <1 cm). However, EphA2 overexpression was significantly associated with higher tumor grade (P = 0.02) and advanced stage of disease (P = 0.001). The median survival for patients with tumor EphA2 overexpression was significantly shorter (median, 3.1 years; P = 0.004); the median survival for patients with low or absent EphA2 tumor expression was at least 12 years and has not yet been reached. In multivariate analysis using the Cox proportional hazards model, only volume of residual disease (P < 0.04) and EphA2 overexpression (P < 0.01) were significant and independent predictors of survival. Conclusions: EphA2 overexpression is predictive of aggressive ovarian cancer behavior and may be an important therapeutic target.
引用
收藏
页码:5145 / 5150
页数:6
相关论文
共 55 条
[21]   RECEPTOR PROTEIN-TYROSINE KINASES AND PHOSPHATASES [J].
HUNTER, T ;
LINDBERG, RA ;
MIDDLEMAS, DS ;
TRACY, S ;
VANDERGEER, P .
COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1992, 57 :25-41
[22]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[23]   Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation [J].
Kikawa, KD ;
Vidale, DR ;
Van Etten, RL ;
Kinch, MS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (42) :39274-39279
[24]   Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer [J].
Kinch, MS ;
Carles-Kinch, K .
CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (01) :59-68
[25]   ALTERED ADHESIONS IN RAS-TRANSFORMED BREAST EPITHELIAL-CELLS [J].
KINCH, MS ;
BURRIDGE, K .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (03) :446-450
[26]   An ephrin mimetic peptide that selectively targets the EphA2 receptor [J].
Koolpe, M ;
Dail, M ;
Pasquale, EB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (49) :46974-46979
[27]  
Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271
[28]   CDNA CLONING AND CHARACTERIZATION OF ECK, AN EPITHELIAL-CELL RECEPTOR PROTEIN-TYROSINE KINASE IN THE EPH ELK FAMILY OF PROTEIN-KINASES [J].
LINDBERG, RA ;
HUNTER, T .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (12) :6316-6324
[29]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6
[30]   Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway [J].
Miao, H ;
Wei, BR ;
Peehl, DM ;
Li, Q ;
Alexandrou, T ;
Schelling, JR ;
Rhim, JS ;
Sedor, JR ;
Burnett, E ;
Wang, BC .
NATURE CELL BIOLOGY, 2001, 3 (05) :527-530